Table 1.
Subjects demographics and clinical measures.
| Measure | Group | Mean | STD | p-value |
|---|---|---|---|---|
| Age (years) | FoG− | 68.6 | 8.4 | 0.77 |
| FoG+ | 69.2 | 7.9 | ||
| Gender | FoG− | 21M-9F | – | |
| FoG+ | 21M-5F | – | ||
| NFoG–Q (score) | FoG− | – | – | |
| FoG+ | 14.3 | 6.4 | ||
| Disease Severity (years) | FoG− | 6.3 | 4.1 | 0.52 |
| FoG+ | 8.3 | 5.3 | ||
| Levodopa Equivalent Dose (mg/day) | FoG− | 711.1 | 360.8 | 0.10 |
| FoG+ | 875.5 | 1320.6 | ||
| MDS-UPDRS III | FoG− | 38.7 | 9.0 | 0.09 |
| FoG+ | 43.1 | 10.0 | ||
| PIGD subscore | FoG− | 4.5 | 2.8 | 0.01 |
| FoG+ | 6.8 | 3.8 | ||
| mini-BEST | FoG− | 19.6 | 4.3 | 0.008 |
| FoG+ | 15.8 | 5.6 | ||
| MoCA | FoG− | 25.0 | 3.2 | 0.75 |
| FoG+ | 24.9 | 4.2 | ||
| Correct answers seated (%) | FoG− | 94.7 | 4.4 | 0.06 |
| FoG+ | 87.6 | 15.9 |
FoG− group (n = 30); FoG+ group (n = 26) Statistically significant differences are bolded.